UroGen Pharma (URGN) - Rasio rega marang prakiraan pendapatan

urogen.com (URGN) - logo korporat

Geopolitical tensions in Israel create challenges for the stability of UroGen Pharma Ltd. (URGN) laboratories, which is confirmed by the forward P/S ratio. The current value of 5.10 describes the actual status of the metric. Risks are linked to stringent ESG standards for reagent disposal; however, the scaling of Jelmyto sales and the anticipation of an FDA verdict serve as powerful drivers for the company's capitalization growth.

urogen.com - Prakiraan rega marang pendapatan URGN (periode 04.07.2022 - 16.11.2026)

UroGen Pharma - rincian analitis lan metrik utama (URGN)

- rega pasar lan target rega analis:
Ringkesan analisis perusahaan:URGN (UroGen Pharma)
Produk asli urogen.com

UroGen Pharma Ltd. (URGN) focuses on urological oncology, mitigating narrow portfolio risks by expanding the application of its gel-based drugs. The projected price-to-sales ratio digitizes this strategy, comparing current market capitalization with expected annual sales. This price action reflects how the market assesses the probability of commercial success for new developments. An increase in this metric signals a premium for business scalability, although it requires close monitoring of the competitive landscape.

Pesaing langsung

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Bicara Therapeutics Inc (BCAX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan personalis.com|Multiplikator forward rega marang pendapatan Erasca Corp (ERAS)|Multiplikator forward rega marang pendapatan DCTH (Delcath)|Rasio kapitalisasi marang dodolan sing dikarepake Y-mAbs Therapeutics, Inc.|Multiplikator Forward P/S AURA (Aura Biosciences Inc)|Rega forward marang dodolan CADL|ARAY: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan CTOR|Rasio rega marang prakiraan pendapatan TuHURA Biosciences Inc.|TARA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|Rasio kapitalisasi marang dodolan sing dikarepake Aadi Bioscience|Rasio rega marang prakiraan pendapatan TScan Therapeutics Inc TCRX|CSBR: Kapitalisasi marang prakiraan pendapatan|XBIT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CVM (cel-sci.com)|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ANL (Adlai Nortye)|Rasio rega marang prakiraan pendapatan Veru Pharma (VERU)|Multiplikator Forward P/S Tempest Tx (TPST)|Rasio rega marang prakiraan pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S